PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Peter C. CANNING	01/06/2010

RECEIVING PARTY DATA

Name:	Eli Lilly and Company
Street Address:	Lilly Corporate Center
City:	Indianapolis
State/Country:	INDIANA
Postal Code:	46285

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	12567627

CORRESPONDENCE DATA

Fax Number: (317)231-7433

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 317-231-6423

Email: gtwyman@btlaw.com

Correspondent Name: James J. Sales

Address Line 1: 11 South Meridian Street

Address Line 2: Barnes & Thornburg LLP

Address Line 4: Indianapolis, INDIANA 46204

ATTORNEY DOCKET NUMBER: X18755_US

NAME OF SUBMITTER: James J. Sales

Total Attachments: 2

source=X18755_US Assignment#page1.tif source=X18755_US Assignment#page2.tif

SH \$40.00 12

PATENT REEL: 023756 FRAME: 0898

ASSIGNMENT

WHEREAS,

Peter C. CANNING 6652 Braemar Avenue Noblesville, IN 46062 US Citizen

is a co-inventor of an invention that is the subject of a patent application ("Application") which is entitled *MODIFIED ANIMAL ERYTHROPOIETIN POLYPEPTIDES AND THEIR USES* containing <u>224</u> pages and <u>37</u> sheets of drawings, for filing:

\boxtimes	in the United States Patent and Trademark Office
	in the United Kingdom Patent Office
	in the European Patent Office
	in the Spanish Patent Office as a European Application
	as an international application under the Patent Cooperation Treaty ("PCT") with United States Patent and Trademark Office acting as Receiving Office

And accorded the following serial number and filing date: 12/567,627, September 25, 2009.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number and filing date for the application when it is known.

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Eli Lilly and Company, its successors and assigns (collectively "Lilly") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Lilly not been made.

> PATENT REEL: 023756 FRAME: 0899

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Lilly that upon request I and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

Date

OCUANZOID

Peter C. CANNING

INDS02 GLT 1087544v1

RECORDED: 01/11/2010

PATENT REEL: 023756 FRAME: 0900